Enno A, O'Rourke J, Braye S, Howlett R, Lee A
School of Pathology, University of New South Wales, Sydney, Australia.
Am J Pathol. 1998 Jun;152(6):1625-32.
In humans, low-grade B-cell mucosa-associated lymphoid tissue (MALT) lymphomas of the stomach regress when Helicobacter pylori infection is cured by antimicrobial therapy. Using an animal model of human gastric MALT lymphoma, we observed the effects of Helicobacter felis eradication and the relationship between infection and disease progression. Antimicrobial therapy was given to one-half of the BALB/c mice infected with H. felis for 20 months. Groups of antibiotic-treated and untreated mice were killed 2, 3, and 4 months after antimicrobial therapy (ie, 22, 23, and 24 months after infection). The numbers of mice with MALT decreased after H. felis eradication with no lymphoid follicles seen 4 months after treatment. MALT lymphoma was present in a total of 23% (11/48) of antibiotic-treated infected mice compared with 75% (27/36) in untreated infected mice. These lymphomas were further graded into low-, intermediate-, and high-grade lymphoma. In the untreated mice, lymphoma development was more advanced with 36% low-grade (13/36), 39% intermediate-grade (14/36), and 6% high-grade (large B-cell) lymphoma (2/36) whereas in the treated mice the incidence was 21% (10/48), 6% (3/48), and 0% (0/48), respectively. These observations suggest that antigenic stimulation by H. felis sustained growth and progression of low-grade MALT lymphoma and that primary high-grade gastric lymphomas can evolve from the transformation of these tumors. Eradication of the organism caused low-grade tumors to regress, with inhibition or slowing down of lymphoma development toward high-grade lymphoma. The H. felis mouse model of gastric MALT lymphoma presents an opportunity to address the issues arising from antimicrobial treatment of these tumors in humans.
在人类中，胃部的低度B细胞黏膜相关淋巴组织（MALT）淋巴瘤在通过抗菌治疗治愈幽门螺杆菌感染后会消退。利用人类胃MALT淋巴瘤的动物模型，我们观察了猫幽门螺杆菌根除的效果以及感染与疾病进展之间的关系。对一半感染猫幽门螺杆菌20个月的BALB/c小鼠进行抗菌治疗。在抗菌治疗后2、3和4个月（即感染后22、23和24个月）处死接受抗生素治疗和未治疗的小鼠组。猫幽门螺杆菌根除后，MALT小鼠数量减少，治疗后4个月未见淋巴滤泡。接受抗生素治疗的感染小鼠中共有23%（11/48）出现MALT淋巴瘤，而未治疗的感染小鼠中这一比例为75%（27/36）。这些淋巴瘤进一步分为低度、中度和高度淋巴瘤。在未治疗的小鼠中，淋巴瘤发展更为严重，低度淋巴瘤占36%（13/36），中度淋巴瘤占39%（14/36），高度（大B细胞）淋巴瘤占6%（2/36）；而在治疗的小鼠中，发病率分别为21%（10/48）、6%（3/48）和0%（0/48）。这些观察结果表明，猫幽门螺杆菌的抗原刺激维持了低度MALT淋巴瘤的生长和进展，原发性高度胃淋巴瘤可能由这些肿瘤的转化演变而来。根除该生物体导致低度肿瘤消退，抑制或减缓淋巴瘤向高度淋巴瘤的发展。胃MALT淋巴瘤的猫幽门螺杆菌小鼠模型为解决人类这些肿瘤抗菌治疗中出现的问题提供了一个机会。
